Blue dye could save lives in sepsis? new trial launches
NCT ID NCT07264543
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if a medicine called methylene blue can help improve blood flow in patients with septic shock, a severe infection that causes dangerously low blood pressure. About 50 adults will receive either methylene blue or standard care for 3 days. The main goal is to see if a larger trial is possible, not yet to prove the drug works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPERFUSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Irmandade da Santa Casa de Misericórdia de Curitiba
RECRUITINGCuritiba, Paraná, 80010-030, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood markers may foretell brain fog after sepsis
- Can tracking immune chaos in sepsis reveal new treatment targets?
- Blood clot score may predict organ damage in septic shock
- Could a key hormone be missing in septic shock?
- Could a simple mineral cut the need for powerful blood-pressure drugs in septic shock?
- Blood filter could shield vessels in septic shock